Cargando…
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-α agents, few studies have examined the long-term effects. We evaluated 511 patients with long-standing refractory rheumatoid arthritis treated with intravenous infusions of infliximab 3 mg...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779428/ https://www.ncbi.nlm.nih.gov/pubmed/16978395 http://dx.doi.org/10.1186/ar2001 |
_version_ | 1782131768883675136 |
---|---|
author | Cruyssen, Bert Vander Van Looy, Stijn Wyns, Bart Westhovens, Rene Durez, Patrick Van den Bosch, Filip Mielants, Herman De Clerck, Luc Peretz, Ann Malaise, Michel Verbruggen, Leon Vastesaeger, Nathan Geldhof, Anja Boullart, Luc De Keyser, Filip |
author_facet | Cruyssen, Bert Vander Van Looy, Stijn Wyns, Bart Westhovens, Rene Durez, Patrick Van den Bosch, Filip Mielants, Herman De Clerck, Luc Peretz, Ann Malaise, Michel Verbruggen, Leon Vastesaeger, Nathan Geldhof, Anja Boullart, Luc De Keyser, Filip |
author_sort | Cruyssen, Bert Vander |
collection | PubMed |
description | Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-α agents, few studies have examined the long-term effects. We evaluated 511 patients with long-standing refractory rheumatoid arthritis treated with intravenous infusions of infliximab 3 mg/kg at weeks 0, 2, 6, and 14 and every 8 weeks thereafter for 4 years. Among the initial 511 patients included in the study, 479 could be evaluated; of these, 295 (61.6%) were still receiving infliximab treatment at year 4 of follow-up. The most common reasons for treatment discontinuation were lack of efficacy (65 patients, 13.6%), safety (81 patients, 16.9%), and elective change (38 patients, 7.9%). Analysis of disease activity scores (DAS28 [disease activity score based on the 28-joint count]) over time showed that, after the initial rapid improvement during the first 6 to 22 weeks of therapy, a further decrease in disease activity of 0.2 units in the DAS28 score per year was observed. DAS28 scores, measured at week 14 or 22, were found to predict subsequent discontinuation due to lack of efficacy. In conclusion, long-term maintenance therapy with infliximab 3 mg/kg is effective in producing further reductions in disease activity. Disease activity measured by the DAS28 at week 14 or 22 of infliximab therapy was the best predictor of long-term attrition. |
format | Text |
id | pubmed-1779428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-17794282007-01-19 Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity Cruyssen, Bert Vander Van Looy, Stijn Wyns, Bart Westhovens, Rene Durez, Patrick Van den Bosch, Filip Mielants, Herman De Clerck, Luc Peretz, Ann Malaise, Michel Verbruggen, Leon Vastesaeger, Nathan Geldhof, Anja Boullart, Luc De Keyser, Filip Arthritis Res Ther Research Article Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-α agents, few studies have examined the long-term effects. We evaluated 511 patients with long-standing refractory rheumatoid arthritis treated with intravenous infusions of infliximab 3 mg/kg at weeks 0, 2, 6, and 14 and every 8 weeks thereafter for 4 years. Among the initial 511 patients included in the study, 479 could be evaluated; of these, 295 (61.6%) were still receiving infliximab treatment at year 4 of follow-up. The most common reasons for treatment discontinuation were lack of efficacy (65 patients, 13.6%), safety (81 patients, 16.9%), and elective change (38 patients, 7.9%). Analysis of disease activity scores (DAS28 [disease activity score based on the 28-joint count]) over time showed that, after the initial rapid improvement during the first 6 to 22 weeks of therapy, a further decrease in disease activity of 0.2 units in the DAS28 score per year was observed. DAS28 scores, measured at week 14 or 22, were found to predict subsequent discontinuation due to lack of efficacy. In conclusion, long-term maintenance therapy with infliximab 3 mg/kg is effective in producing further reductions in disease activity. Disease activity measured by the DAS28 at week 14 or 22 of infliximab therapy was the best predictor of long-term attrition. BioMed Central 2006 2006-07-17 /pmc/articles/PMC1779428/ /pubmed/16978395 http://dx.doi.org/10.1186/ar2001 Text en Copyright © 2006 Vander Cruyssen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Cruyssen, Bert Vander Van Looy, Stijn Wyns, Bart Westhovens, Rene Durez, Patrick Van den Bosch, Filip Mielants, Herman De Clerck, Luc Peretz, Ann Malaise, Michel Verbruggen, Leon Vastesaeger, Nathan Geldhof, Anja Boullart, Luc De Keyser, Filip Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity |
title | Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity |
title_full | Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity |
title_fullStr | Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity |
title_full_unstemmed | Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity |
title_short | Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity |
title_sort | four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779428/ https://www.ncbi.nlm.nih.gov/pubmed/16978395 http://dx.doi.org/10.1186/ar2001 |
work_keys_str_mv | AT cruyssenbertvander fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT vanlooystijn fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT wynsbart fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT westhovensrene fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT durezpatrick fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT vandenboschfilip fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT mielantsherman fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT declerckluc fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT peretzann fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT malaisemichel fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT verbruggenleon fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT vastesaegernathan fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT geldhofanja fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT boullartluc fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity AT dekeyserfilip fouryearfollowupofinfliximabtherapyinrheumatoidarthritispatientswithlongstandingrefractorydiseaseattritionandlongtermevolutionofdiseaseactivity |